BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002;25:707-712. [PMID: 12167066 DOI: 10.2165/00002018-200225100-00003] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Andrews LM, Hesselink DA, van Gelder T, Koch BCP, Cornelissen EAM, Brüggemann RJM, van Schaik RHN, de Wildt SN, Cransberg K, de Winter BCM. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. Clin Pharmacokinet 2018;57:475-89. [PMID: 28681225 DOI: 10.1007/s40262-017-0567-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
2 Al-lawati H, Aliabadi HM, Makhmalzadeh BS, Lavasanifar A. Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research. Expert Opinion on Drug Delivery 2018;15:397-418. [DOI: 10.1080/17425247.2018.1420053] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
3 Vicari-christensen M, Repper S, Basile S, Young D. Tacrolimus: Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics to Facilitate Practitioners' Understanding and Offer Strategies for Educating Patients and Promoting Adherence. Prog Transpl 2009;19:277-84. [DOI: 10.1177/152692480901900315] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
4 Pashaee N, Bouamar R, Hesselink DA, Roodnat JI, van Schaik RH, Weimar W, van Gelder T. CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance. Ther Drug Monit 2011;33:369-71. [PMID: 21566507 DOI: 10.1097/FTD.0b013e31821a7aa3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
5 Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52:2439-46. [DOI: 10.1002/art.21240] [Cited by in Crossref: 165] [Cited by in F6Publishing: 123] [Article Influence: 9.7] [Reference Citation Analysis]
6 Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando). 2015;29:78-84. [PMID: 25687818 DOI: 10.1016/j.trre.2015.01.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 14.9] [Reference Citation Analysis]
7 Lin S, Henning AK, Akhlaghi F, Reisfield R, Vergara-silva A, First MR. Interleukin-2 Receptor Antagonist Therapy Leads to Increased Tacrolimus Levels After Kidney Transplantation. Therapeutic Drug Monitoring 2015;37:206-13. [DOI: 10.1097/ftd.0000000000000125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
8 Moreau C, Debray D, Loriot MA, Taburet AM, Furlan V. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. Transplantation 2006;81:487-8. [PMID: 16477241 DOI: 10.1097/01.tp.0000194861.59543.b9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
9 Katsakiori PF, Papapetrou EP, Goumenos DS, Nikiforidis GC, Flordellis CS. Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients. Ther Clin Risk Manag 2010;6:265-9. [PMID: 20596503 DOI: 10.2147/tcrm.s11501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
10 Andrews LM, Hesselink DA, van Schaik RHN, van Gelder T, de Fijter JW, Lloberas N, Elens L, Moes DJAR, de Winter BCM. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol 2019;85:601-15. [PMID: 30552703 DOI: 10.1111/bcp.13838] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
11 Sapir-pichhadze R, Tinckam K, Quach K, Logan A, Laupacis A, John R, Beyene J, Kim S. HLA-DR and -DQ Eplet Mismatches and Transplant Glomerulopathy: A Nested Case-Control Study: HLA-DR + DQ Eplet Mismatches and TG. American Journal of Transplantation 2015;15:137-48. [DOI: 10.1111/ajt.12968] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 10.5] [Reference Citation Analysis]
12 Andrews LM, de Winter BCM, Cornelissen EAM, de Jong H, Hesselink DA, Schreuder MF, Brüggemann RJM, van Gelder T, Cransberg K. A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. Clin Pharmacokinet 2020;59:591-603. [PMID: 31654367 DOI: 10.1007/s40262-019-00831-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, Culver D, Harrod CG, Hayney MS, Highland KB, Limper AH, Patrick H, Strange C, Whelan T. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;142:e1S-e111S. [PMID: 23131960 DOI: 10.1378/chest.12-1044] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
14 Staatz CE, Tett SE. Pharmacokinetic Considerations Relating to Tacrolimus Dosing in the Elderly: . Drugs & Aging 2005;22:541-57. [DOI: 10.2165/00002512-200522070-00001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
15 Sansone-parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of Oral Posaconazole on the Pharmacokinetics of Cyclosporine and Tacrolimus. Pharmacotherapy 2007;27:825-34. [DOI: 10.1592/phco.27.6.825] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 6.3] [Reference Citation Analysis]
16 Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 2004;43:741-62. [PMID: 15301578 DOI: 10.2165/00003088-200443110-00005] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 5.1] [Reference Citation Analysis]
17 Venkat VL, Nick TG, Wang Y, Bucuvalas JC. An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence. Pediatr Transplant 2008;12:67-72. [PMID: 18186891 DOI: 10.1111/j.1399-3046.2007.00794.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
18 Han SS, Yang SH, Kim MC, Cho JY, Min SI, Lee JP, Kim DK, Ha J, Kim YS. Monitoring the Intracellular Tacrolimus Concentration in Kidney Transplant Recipients with Stable Graft Function. PLoS One 2016;11:e0153491. [PMID: 27082871 DOI: 10.1371/journal.pone.0153491] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
19 Birdwell KA, Grady B, Choi L, Xu H, Bian A, Denny JC, Jiang M, Vranic G, Basford M, Cowan JD, Richardson DM, Robinson MP, Ikizler TA, Ritchie MD, Stein CM, Haas DW. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genomics 2012;22:32-42. [PMID: 22108237 DOI: 10.1097/FPC.0b013e32834e1641] [Cited by in Crossref: 74] [Cited by in F6Publishing: 42] [Article Influence: 7.4] [Reference Citation Analysis]
20 Cajanding R. Immunosuppression following organ transplantation. Part 1: mechanisms and immunosuppressive agents. Br J Nurs 2018;27:920-7. [PMID: 30187798 DOI: 10.12968/bjon.2018.27.16.920] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Konishi H, Sumi M, Shibata N, Takada K, Minouchi T, Yamaji A. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. J Pharm Pharmacol 2004;56:1259-66. [PMID: 15482640 DOI: 10.1211/0022357044481] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
22 Chen X, Wang D, Xu H, Li Z. Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics. Expert Review of Clinical Pharmacology 2020;13:553-61. [DOI: 10.1080/17512433.2020.1767592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Borrows R, Chusney G, Loucaidou M, James A, Goel S, Borrows S, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D. Analysis of factors influencing tacrolimus levels and immunoassay bias in renal transplantation. J Clin Pharmacol 2007;47:1035-42. [PMID: 17660485 DOI: 10.1177/0091270007303765] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
24 Scheel J, Reber S, Stoessel L, Waldmann E, Jank S, Eckardt KU, Grundmann F, Vitinius F, de Zwaan M, Bertram A, Erim Y. Patient-reported non-adherence and immunosuppressant trough levels are associated with rejection after renal transplantation. BMC Nephrol 2017;18:107. [PMID: 28356080 DOI: 10.1186/s12882-017-0517-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
25 Qin XL, Bi HC, Wang CX, Li JL, Wang XD, Liu LS, Chen X, Huang M. Study of the effect of Wuzhi tablet (Schisandra sphenanthera extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. Biomed Chromatogr 2010;24:399-405. [PMID: 19693766 DOI: 10.1002/bmc.1305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
26 Staatz CE, Tett SE. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Clin Pharmacokinet 2015;54:993-1025. [DOI: 10.1007/s40262-015-0282-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
27 Kuypers DR, Vanrenterghem Y. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. Clin Ther 2004;26:1834-44. [PMID: 15639695 DOI: 10.1016/j.clinthera.2004.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
28 Qin XL, Bi HC, Wang XD, Li JL, Wang Y, Xue XP, Chen X, Wang CX, Xu LJ, Wang YT, Huang M. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). International Journal of Pharmaceutics 2010;389:114-21. [DOI: 10.1016/j.ijpharm.2010.01.025] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
29 Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 2013;23:563-85. [PMID: 23922006 DOI: 10.1097/FPC.0b013e328364db84] [Cited by in Crossref: 119] [Cited by in F6Publishing: 46] [Article Influence: 14.9] [Reference Citation Analysis]
30 Tönshoff B. Immunosuppressants in Organ Transplantation. Handb Exp Pharmacol 2020;261:441-69. [PMID: 31820175 DOI: 10.1007/164_2019_331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Naniwa T, Iwagaitsu S, Kajiura M. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors. Int J Rheum Dis 2018;21:673-87. [PMID: 29314738 DOI: 10.1111/1756-185X.13248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
32 Budde K, Giessing M, Liefeldt L, Neumayer HH, Glander P. [Modern immunosuppression following renal transplantation. Standard or tailor made?]. Urologe A 2006;45:9-17. [PMID: 16328215 DOI: 10.1007/s00120-005-0958-6] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
33 Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen M, Elens L, Johnson-davis KL, Kunicki PK, Macphee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring 2019;41:261-307. [DOI: 10.1097/ftd.0000000000000640] [Cited by in Crossref: 131] [Cited by in F6Publishing: 46] [Article Influence: 43.7] [Reference Citation Analysis]
34 Cheng S, Tang M, Du J, Yin T. Effects of antifungal drugs on the plasma concentrations and dosage of tacrolimus in kidney transplant patients. Eur J Hosp Pharm 2020:ejhpharm-2020-002385. [PMID: 33020057 DOI: 10.1136/ejhpharm-2020-002385] [Reference Citation Analysis]
35 Bloom RD, Trofe-clark J, Wiland A, Alloway RR. A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients. Clin Transplant 2013;27:E685-93. [DOI: 10.1111/ctr.12256] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
36 Prytuła A, van Gelder T. Clinical aspects of tacrolimus use in paediatric renal transplant recipients. Pediatr Nephrol 2019;34:31-43. [DOI: 10.1007/s00467-018-3892-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
37 Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. Transplantation 2017;101:e273-9. [DOI: 10.1097/tp.0000000000001796] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 5.6] [Reference Citation Analysis]
38 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
39 Oswald S, Nassif A, Modess C, Keiser M, Ulrich A, Runge D, Hanke U, Lütjohann D, Engel A, Weitschies W, Siegmund W. Drug Interactions Between the Immunosuppressant Tacrolimus and the Cholesterol Absorption Inhibitor Ezetimibe in Healthy Volunteers. Clin Pharmacol Ther 2011;89:524-8. [DOI: 10.1038/clpt.2011.4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
40 Budde K, Glander P, Diekmann F, Waiser J, Fritsche L, Dragun D, Neumayer HH. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004;5:1333-45. [PMID: 15163278 DOI: 10.1517/14656566.5.6.1333] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
41 . Immunosuppressive drug interactions with anti-infective agents. Am J Transplant 2004;4 Suppl 10:164-6. [PMID: 15504230 DOI: 10.1111/j.1600-6135.2004.00738.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
42 Chen L, Lu X, Tan G, Zhu L, Liu Y, Li M. Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients. Xenobiotica 2020;50:196-201. [DOI: 10.1080/00498254.2019.1607918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
43 Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623-53. [PMID: 15244495 DOI: 10.2165/00003088-200443100-00001] [Cited by in Crossref: 528] [Cited by in F6Publishing: 462] [Article Influence: 29.3] [Reference Citation Analysis]
44 Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247-1297. [PMID: 12790696 DOI: 10.2165/00003495-200363120-00006] [Cited by in Crossref: 308] [Cited by in F6Publishing: 260] [Article Influence: 16.2] [Reference Citation Analysis]
45 Qin XL, Chen X, Wang Y, Xue XP, Wang Y, Li JL, Wang XD, Zhong GP, Wang CX, Yang H, Huang M, Bi HC. In Vivo to In Vitro Effects of Six Bioactive Lignans of Wuzhi Tablet ( Schisandra Sphenanthera Extract ) on the CYP3A/P-glycoprotein–Mediated Absorption and Metabolism of Tacrolimus. Drug Metab Dispos 2013;42:193-9. [DOI: 10.1124/dmd.113.053892] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
46 Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother 2008;9:635-43. [PMID: 18312164 DOI: 10.1517/14656566.9.4.635] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
47 Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Yamamoto R, Habuchi T, Satoh S, Miura M. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations. Clin Exp Nephrol 2017;21:787-96. [DOI: 10.1007/s10157-016-1375-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
48 Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int 2014;85:1404-11. [PMID: 24336032 DOI: 10.1038/ki.2013.465] [Cited by in Crossref: 123] [Cited by in F6Publishing: 111] [Article Influence: 13.7] [Reference Citation Analysis]
49 Udomkarnjananun S, Francke MI, De Winter BCM, Mulder MB, Baan CC, Metselaar HJ, den Hoed CM, Hesselink DA. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101756. [PMID: 34874840 DOI: 10.1016/j.bpg.2021.101756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Jacobson PA, Oetting WS, Brearley AM, Leduc R, Guan W, Schladt D, Matas AJ, Lamba V, Julian BA, Mannon RB, Israni A; DeKAF Investigators. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011;91:300-308. [PMID: 21206424 DOI: 10.1097/tp.0b013e318200e991] [Cited by in Crossref: 123] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
51 Shullo MA, Schonder K, Teuteberg JJ. Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: a case report. Transplant Proc 2010;42:1870-2. [PMID: 20620540 DOI: 10.1016/j.transproceed.2010.02.095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
52 Goodall DL, Willicombe M, McLean AG, Taube D. High Intrapatient Variability of Tacrolimus Levels and Outpatient Clinic Nonattendance Are Associated With Inferior Outcomes in Renal Transplant Patients. Transplant Direct 2017;3:e192. [PMID: 28795143 DOI: 10.1097/TXD.0000000000000710] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 6.4] [Reference Citation Analysis]
53 Wang D, Chen X, Li Z. Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. J Clin Pharm Ther 2019;44:611-7. [DOI: 10.1111/jcpt.12828] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
54 Kitamura A, Mizuno Y, Natsui K, Yabuki M, Komuro S, Kanamaru H. Characterization of human cytochrome P450 enzymes involved in thein vitro metabolism of perospirone. Biopharm Drug Dispos 2005;26:59-65. [DOI: 10.1002/bdd.432] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
55 Drabant S, Tóth M, Bereczki A, Bajnógel J, Tömlö J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. Eur J Clin Pharmacol 2006;62:587-8. [PMID: 16791582 DOI: 10.1007/s00228-006-0160-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
56 Chen L, Yang Y, Wang X, Wang C, Lin W, Jiao Z, Wang Z. Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis. Pharmgenomics Pers Med 2021;14:1093-106. [PMID: 34511980 DOI: 10.2147/PGPM.S321997] [Reference Citation Analysis]
57 Fireman M, Dimartini AF, Armstrong SC, Cozza KL. Immunosuppressants. Psychosomatics 2004;45:354-60. [DOI: 10.1176/appi.psy.45.4.354] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
58 Choi J, Chandraker A. Immunologic Risk Assessment and Approach to Immunosuppression Regimen in Kidney Transplantation. Clin Lab Med 2019;39:643-56. [PMID: 31668275 DOI: 10.1016/j.cll.2019.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Vicari-Christensen M, Repper S, Basile S, Young D. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog Transplant 2009;19:277-84. [PMID: 19813492 DOI: 10.7182/prtr.19.3.22u4114wn0l01140] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
60 Wei H, Tao X, Di P, Yang Y, Li J, Qian X, Feng J, Chen W. Effects of Traditional Chinese Medicine Wuzhi Capsule on Pharmacokinetics of Tacrolimus in Rats. Drug Metab Dispos 2013;41:1398-403. [DOI: 10.1124/dmd.112.050302] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
61 Süsal C, Döhler B. Late intra‐patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report. Am J Transplant 2019;19:2805-13. [DOI: 10.1111/ajt.15346] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
62 Bucuvalas JC, Ryckman FC, Arya G, Andrew B, Lesko A, Cole CR, James B, Kotagal U. A Novel Approach to Managing Variation: Outpatient Therapeutic Monitoring of Calcineurin Inhibitor Blood Levels in Liver Transplant Recipients. The Journal of Pediatrics 2005;146:744-50. [DOI: 10.1016/j.jpeds.2005.01.036] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
63 Lloberas N, Elens L, Llaudó I, Padullés A, van Gelder T, Hesselink DA, Colom H, Andreu F, Torras J, Bestard O, Cruzado JM, Gil-vernet S, van Schaik R, Grinyó JM. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. Pharmacogenetics and Genomics 2017;27:313-22. [DOI: 10.1097/fpc.0000000000000296] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 5.4] [Reference Citation Analysis]
64 Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, Kuypers D, Le Meur Y, Marquet P, Oellerich M, Thervet E, Toenshoff B, Undre N, Weber LT, Westley IS, Mourad M. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009;31:139-52. [PMID: 19177031 DOI: 10.1097/FTD.0b013e318198d092] [Cited by in Crossref: 330] [Cited by in F6Publishing: 86] [Article Influence: 25.4] [Reference Citation Analysis]
65 Leino AD, King EC, Jiang W, Vinks AA, Klawitter J, Christians U, Woodle ES, Alloway RR, Rohan JM. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am J Transplant 2019;19:1410-20. [DOI: 10.1111/ajt.15199] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
66 Pollock-Barziv SM, Finkelstein Y, Manlhiot C, Dipchand AI, Hebert D, Ng VL, Solomon M, McCrindle BW, Grant D. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant. 2010;14:968-975. [PMID: 21040278 DOI: 10.1111/j.1399-3046.2010.01409.x] [Cited by in Crossref: 118] [Cited by in F6Publishing: 109] [Article Influence: 9.8] [Reference Citation Analysis]
67 Wungwattana M, Savic M. Tacrolimus interaction with nafcillin resulting in significant decreases in tacrolimus concentrations: A case report. Transpl Infect Dis 2017;19. [PMID: 28067989 DOI: 10.1111/tid.12662] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Degraeve AL, Moudio S, Haufroid V, Chaib Eddour D, Mourad M, Bindels LB, Elens L. Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opin Drug Metab Toxicol 2020;16:769-82. [PMID: 32721175 DOI: 10.1080/17425255.2020.1803277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
69 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
70 Prytuła AA, Cransberg K, Bouts AH, van Schaik RH, de Jong H, de Wildt SN, Mathôt RA. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Clin Pharmacokinet 2016;55:1129-43. [PMID: 27138785 DOI: 10.1007/s40262-016-0390-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
71 Eskander MA, Adler E, Hoffmayer KS. Arrhythmias and sudden cardiac death in post-cardiac transplant patients. Current Opinion in Cardiology 2020;35:308-11. [DOI: 10.1097/hco.0000000000000731] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Malvezzi P, Rostaing L. The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opinion on Drug Safety 2015;14:1531-46. [DOI: 10.1517/14740338.2015.1083974] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
73 Tóth M, Drabant S, Varga B, Végso G, Cseh A, Szentpéteri I, Klebovich I. Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam. Eur J Clin Pharmacol 2008;64:93-4. [PMID: 17989974 DOI: 10.1007/s00228-007-0397-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
74 Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of Pharmacokinetic Interaction Between Anidulafungin and Tacrolimus. The Journal of Clinical Pharmacology 2007;47:305-14. [DOI: 10.1177/0091270006296764] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
75 Heinrich TW, Marcangelo M. Psychiatric issues in solid organ transplantation. Harv Rev Psychiatry. 2009;17:398-406. [PMID: 19968454 DOI: 10.3109/10673220903463259] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
76 Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98:19-24. [PMID: 25801146 DOI: 10.1002/cpt.113] [Cited by in Crossref: 279] [Cited by in F6Publishing: 247] [Article Influence: 39.9] [Reference Citation Analysis]
77 Fan Z, Zheng D, Wen X, Shen F, Lei L, Su S, Zhang S, Liu Q, Zhang X, Lu Y, Di L, Shen XM, Da Y. CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients. J Neuroimmunol 2021;355:577571. [PMID: 33866281 DOI: 10.1016/j.jneuroim.2021.577571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Kropeit D, von Richter O, Stobernack HP, Rübsamen-Schaeff H, Zimmermann H. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. Clin Pharmacol Drug Dev 2018;7:9-21. [PMID: 28967706 DOI: 10.1002/cpdd.388] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 8.6] [Reference Citation Analysis]
79 Mendonza AE, Zahir H, Gohh RY, Akhlaghi F. Tacrolimus in Diabetic Kidney Transplant Recipients: Pharmacokinetics and Application of a Limited Sampling Strategy. Therapeutic Drug Monitoring 2007;29:391-8. [DOI: 10.1097/ftd.0b013e31811f319b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
80 Andrews LM, Riva N, de Winter BC, Hesselink DA, de Wildt SN, Cransberg K, van Gelder T. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opinion on Drug Metabolism & Toxicology 2015;11:921-36. [DOI: 10.1517/17425255.2015.1033397] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]